Citius Oncology, Inc. - Common Stock CTOR 深 滬
等待開盤 07-19 09:30:00 美东时间
1.53
-0.070
-4.37%
華盛通- 最 高1.72
- 今 開1.60
- 成交量 57.32万股
- 最 低 1.52
- 昨 收 1.60
- 總市值 1.09亿
- 52周最高 49.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.5506
- 委 比 10.53%
- 總股本 7155.24万
- 歷史最高 49.00
- 量 比 0.14
- 振 幅 12.50%
- 歷史最低 0.00
- 每 手 1
- 風險率 6.19%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Citius Oncology Announces Pricing of $9.0 Million Public Offering
CRANFORD, N.J., July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: ...
07-16 21:15
Cencora distribution deal boosts Citius shares
Citius Pharmaceuticals (NASDAQ:CTXR) traded higher in the premarket on Tuesday after the company announced that its majority-owned subsidiary, Citius Oncology (NASDAQ:CTOR), reached a distribution ser...
07-15 20:56
Citius Oncology Partners With Cencora To Boost Commercial Launch And Distribution Of FDA-Approved Immunotherapy LYMPHIR
Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™CRANFORD, N.J., July 15, 2025 /PRNewswire/ --
07-15 20:35
Citius Oncology launches $15M equity and warrant offering; shares down
Citius Oncology (NASDAQ:CTOR) is offering up to $15M in common stock and accompanying warrants. The offering includes up to $15M in pre-funded warrants and up to $15M in regular warrants, each convert...
07-14 22:51
减持速报 | 超图软件(300036.SZ)实控人等拟集体减持，真爱美家(003041.SZ)大股东拟减持3%
1.埃夫特(688165.SH)：股东信惟基石及其一致行动人马鞍山基石计划通过集中竞价和大宗交易方式减持公司股份，不超过13,044,500股，占公...
07-09 09:04
Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention
Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs c...
07-08 22:25
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER
At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone THOUSAND OAKS, Calif., Jun...
06-30 21:00
Citius Oncology Regains Nasdaq Compliance June 2025
Citius Oncology ( ($CTOR) ) has issued an update. On June 26, 2025, Citius Onco...
06-28 05:31
Catalyst Watch: Jobs Report, Tesla deliveries, Constellation Brands earnings, and Circle ratings
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - June 30 V...
06-28 03:00
